Therapeutic intrauterine system (ius) placed in the tube of the conductor. The system consists of a white or almost white hormone-elastomer core, placed on a T-shaped housing and covered with an opaque membrane that regulates the release of levonorgestrel. T-shaped housing is provided with a loop on one end and two shoulders on the other. Attached to the loop of the thread to remove the system. System Explorer is free from visible impurities.
Pharmacokinetics:
Absorption. After the introduction of the Mirena in the uterus begins to immediately release levonorgestrel.
High local drug exposure in the uterine cavity, is necessary for the local effects of Mirena on the endometrium, provides a high concentration gradient in the direction from the endometrium to the myometrium (the concentration of levonorgestrel in the endometrium is greater than its concentration in the myometrium more than 100-fold) and low concentrations of levonorgestrel in serum (concentration of levonorgestrel in the endometrium higher than the concentration in the serum of more than 1000 times).
The rate of release of levonorgestrel in the uterine cavity in vivo is initially approximately 20 µg/day, and in 5 years be reduced to 10 mg/day.
